A Randomised, Double-Blind, Placebo-Controlled, Multi-Centre, Phase III Study to Assess Efficacy and Safety of STALORAL 300 IR Sublingual Immunotherapy (SLIT) in Chinese Asthmatic Patients Allergic to House-Dust Mites

Trial Profile

A Randomised, Double-Blind, Placebo-Controlled, Multi-Centre, Phase III Study to Assess Efficacy and Safety of STALORAL 300 IR Sublingual Immunotherapy (SLIT) in Chinese Asthmatic Patients Allergic to House-Dust Mites

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Jul 2017

At a glance

  • Drugs House dust mite allergy immunotherapy (Primary)
  • Indications Allergic asthma; Hypersensitivity
  • Focus Registrational; Therapeutic Use
  • Sponsors Stallergenes SA
  • Most Recent Events

    • 14 Oct 2015 Results published in the Allergy
    • 11 Oct 2011 Actual end date Jul 2009 added as reported by ClinicalTrials.gov.
    • 21 Jun 2010 Status changed from active, no longer recruiting to completed, according to a Stallergenes SA media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top